ChonlutenvsCartalax

Molecular Formula

C₁₁H₁₇N₃O₈

Molecular Weight

319.27 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure

CAS Number

75007-24-8

Molecular Formula

C₁₂H₁₉N₃O₈

Molecular Weight

333.3 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids

Bioavailability

Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)

CAS Number

Not yet registered (research compound)

Common

• Injection site reaction
• Mild fatigue
• Transient respiratory changes
• Mild headache

Uncommon

• Flu-like symptoms

Serious

• No documented serious adverse effects

Common

• Mild injection site reaction
• Mild GI discomfort
• Mild fatigue
• Transient joint stiffness

Uncommon

• Temporary increase in joint discomfort

Serious

• No documented serious adverse effects

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive pulmonary infections requiring immediate medical treatment
• xSevere immunosuppression without medical supervision — immunomodulatory effects may be unpredictable

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive joint infection — treat infection before initiating peptide bioregulator therapy
• xMalignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated